تیموکینون در پیشگیری از نارسایی حاد کلیوی ناشی از جنتامایسین:خلاصه سیاستی

Background:Acute kidney injury (AKI) is a common and costly complication of pharmacological therapies in hospitalized patients, particularly among those receiving aminoglycoside antibiotics such as gentamicin. Despite its high efficacy in treating severe Gram-negative infections, the clinical use of gentamicin is limited by its well-documented nephrotoxicity.
This policy-oriented paper aims to analyze the available experimental evidence on the nephroprotective effects of thymoquinone—the principal bioactive compound of Nigella sativa (black seed)—and to explore its translational and policy implications for the Iranian health system.
Preclinical studies suggest that thymoquinone mitigates gentamicin-induced renal injury through suppression of oxidative stress and modulation of inflammatory pathways. Experimental findings indicate improvements in biochemical markers of renal function, attenuation of lipid peroxidation, enhancement of endogenous antioxidant defense systems, and reduction of pro-inflammatory mediators. These mechanisms are consistent with the established pathophysiology of aminoglycoside-induced nephrotoxicity. Although current evidence remains at the preclinical level, the biological plausibility and consistency of findings provide a rationale for further translational research. Targeted support for early-phase clinical trials, development of regulatory frameworks for standardized thymoquinone formulations, and comprehensive cost-effectiveness analyses are necessary steps toward potential clinical implementation. If safety and efficacy are confirmed in human studies, thymoquinone may represent a complementary strategy to reduce drug-induced AKI and its associated clinical and economic burden in Iran. Thymoquinone emerges as a promising adjunctive candidate for preventing gentamicin-associated nephrotoxicity. A structured translational pathway is essential before integration into clinical practice; however, its development may offer meaningful clinical and health policy benefits for the Iranian healthcare system.